TAR 200 – Talk Bio

As J&J aims to ‘fundamentally change’ how bladder cancer type is treated, ImmunityBio plays defense

1 month ago talkbio0Tagged Anktiva, BCG-Unresponsive, bladder-sparing treatment, Carcinoma in Situ, gemcitabine releasing system, ImmunityBio, in situ, Malignant neoplasm of urinary bladder, Non-Muscle Invasive Bladder Neoplasms, TAR 200

TAR-200, bladder cancer, gemcitabine releasing system, non-muscle invasive bladder cancer (NMIBC), Johnson & Johnson, ImmunityBio, Anktiva, BCG-unresponsive, carcinoma in situ (CIS), bladder-sparing treatment

J&J reports durability data for bladder cancer ‘pretzel’ drug after FDA filing

1 month ago talkbio0Tagged Malignant neoplasm of urinary bladder, TAR 200, United States Food and Drug Administration, Urinary Bladder

Urinary Bladder, TAR 200, United States Food and Drug Administration, Malignant neoplasm of urinary bladder

Johnson & Johnson’s Bladder Cancer Treatment Falls Short Against Chemoradiation

8 months ago talkbio0Tagged Chemoradiotherapy, Johnson and Johnson, Malignant neoplasm of urinary bladder, SunRISe-1, TAR 200

Johnson & Johnson, bladder cancer, chemoradiation, TAR-200, SunRISe-1 study